Merck

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Ambrosia Biosciences is a drug discovery company focused on developing small molecule-based therapies for obesity and other metabolic disorders. The company provides innovative, non-invasive methods for weight management and improving metabolic health, allowing patients to manage their conditions more effectively with fewer side effects than traditional medications. Through its research and development efforts, Ambrosia Biosciences aims to address the growing challenges associated with obesity and related metabolic issues.

UnitySC is a globally recognized leader in inspection and metrology, specializing in advanced technologies such as automated optical inspection and 3D imaging. By offering customized solutions tailored to specific industrial requirements, UnitySC empowers customers to enhance yields and accelerate time to market. Through innovative techniques like high depth of focus line scanning and spectrometry, UnitySC enables a new era in process control, facilitating efficient and precise manufacturing operations.

Proteologix is a precision immunology company powered by proprietary multi-specific antibody technologies. The company is dedicated to the discovery and development of safe and convenient therapeutics that target multiple disease-driving pathways to potentially deliver high-bar efficacy for patients with immune-mediated diseases.

Eurocine Vaccines specializes in developing nasal flu vaccines aimed at children and the elderly. The company oversees all aspects of vaccine development, which encompasses preclinical and clinical trials, manufacturing scalability, business development, and securing funding. Through this comprehensive approach, Eurocine Vaccines seeks to enhance immunization options and improve public health outcomes.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Chord Therapeutics is a biotechnology company based in Geneva, Switzerland, focused on developing treatments for rare, life-threatening neurological diseases. Established in 2014, the company specializes in repurposing small molecule drugs to create effective therapies. Its lead product, CRD1, is being advanced under orphan drug designation for conditions such as neuromyelitis optica spectrum disorders and myasthenia gravis. Chord Therapeutics aims to provide solutions that significantly improve the lives of patients affected by these severely disabling illnesses.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Chekkit is a technology company that provides an anti-counterfeiting solution powered by a DAG blockchain, specifically designed for the food and drug supply chain. The platform enables producers to protect their brands by offering real-time product authentication and tracking of supply chain activities. Additionally, Chekkit facilitates consumer engagement and collects valuable insights from the last mile of the supply chain. By equipping producers of fast-moving consumer goods (FMCG) and pharmaceuticals with tools to combat counterfeiting, Chekkit helps them regain market share and enhance sales while ensuring the integrity of their products.

Formo is a pioneering cellular agriculture company based in Europe that specializes in creating animal-free dairy products. By utilizing precision fermentation, Formo develops real, nature-identical milk proteins, allowing for the production of clean dairy alternatives. The company aims to provide sustainable and healthy options for consumers, particularly those seeking vegan food products. Through innovative biotechnology, Formo transforms nutrients into dairy proteins, contributing to a more equitable and environmentally friendly approach to dairy consumption.

Chekkit is a technology company that provides an anti-counterfeiting solution powered by a DAG blockchain, specifically designed for the food and drug supply chain. The platform enables producers to protect their brands by offering real-time product authentication and tracking of supply chain activities. Additionally, Chekkit facilitates consumer engagement and collects valuable insights from the last mile of the supply chain. By equipping producers of fast-moving consumer goods (FMCG) and pharmaceuticals with tools to combat counterfeiting, Chekkit helps them regain market share and enhance sales while ensuring the integrity of their products.

Akili Labs is a biomedical startup based in South Africa that specializes in developing medical diagnostic technology to enhance healthcare through improved diagnostics. Founded in 2017 by Charles Faul and Lucas Lotter, with Dr. Farhan Pervaiz joining as a co-founder in 2018, the company aims to address the need for rapid diagnoses within the healthcare system. Akili Labs focuses on creating molecular diagnostic tools capable of testing for various infections and enabling gene screening. Their innovative and location-appropriate diagnostic systems are designed to reduce costs and improve access to healthcare services across Africa. The company actively collaborates with global organizations to develop and implement healthcare and diagnostic-related products, emphasizing innovation and partnership in its mission.

Bluewave offer end to end product and process design for technology driven insurance solutions ensuring that products are accessible

Epilert is a Tunis-based company founded in 2017 that specializes in wearable technology for individuals with neurological conditions, particularly epilepsy. The company has developed an artificial intelligence-based bracelet that detects seizures by utilizing sensors and machine learning algorithms. This bracelet provides real-time data collection and alerts caregivers through a connected application when irregularities are detected. Additionally, the technology tracks physical activity and sleep patterns, enhancing the overall support for users in their daily lives and improving access to healthcare when needed.

Intermolecular, Inc. specializes in the development of advanced materials through its high productivity combinatorial (HPC) technology platform, targeting various industries such as semiconductors, consumer electronics, automotive, and aerospace. The company's HPC platform includes the Tempus processing tools, automated characterization methods, and informatics analysis software, which facilitate materials discovery and process development. Intermolecular's offerings encompass wet workflow systems for self-assembly, electroless deposition, and surface preparation, as well as atomic layer deposition (ALD) and physical vapor deposition (PVD) systems. The company serves a diverse range of markets, including semiconductor, biotechnology, and energy sectors, with a significant focus on the Asia-Pacific region. Founded in 2004 and headquartered in San Jose, California, Intermolecular operates as a subsidiary of MERCK Kommanditgesellschaft auf Aktien.

Versum Materials, Inc. is a global provider of specialty materials specifically designed for the semiconductor and display industries, with operations in the United States, Taiwan, South Korea, China, Europe, and other regions in Asia. The company operates through two main segments: Materials and Delivery Systems and Services (DS&S). The Materials segment offers a range of high-purity chemicals and gases utilized in semiconductor manufacturing, including materials for deposition, metallization, and cleaning processes, as well as chemical slurries and organometallics. The DS&S segment focuses on the development and manufacturing of systems for managing the delivery of gases and chemicals, alongside providing project management, maintenance services, and on-site support to optimize the inventory and operations of these materials. Founded in 2015 and headquartered in Tempe, Arizona, Versum Materials emphasizes collaboration and innovation to address the evolving needs of its customers in the high-tech materials sector.

Mosaic is a technology company that provides children's precise development and professional rehabilitation services.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

Grzybowski Scientific Inventions (GSI) is a start-up company with exclusive licensing, development, marketing and sales rights to the revolutionary chemistry decision-making and synthetic planning software product Chematica. Since its establishment in December 2013, GSI has successfully engaged a clientele composed of a wide range of industries as well as academic and government institutions from all over the world.

Clustermarket LTD. operates an online platform that streamlines resource sharing for research in the life sciences sector. Established in 2015 and based in London, the company facilitates access to a wide range of resources, including equipment, software, services, and lab space. By allowing scientists to list, discover, and book these resources, Clustermarket supports various institutions, from small startups to large universities. The platform serves as a comprehensive lab management solution, enabling users to create personal accounts, post requirements, and connect with service providers, thereby democratizing access to expensive research tools and services. Ultimately, Clustermarket aims to accelerate the journey from innovative ideas to market-ready solutions in the life sciences industry.

Fresh Strips is a smart packaging company that specializes in providing cost-effective solutions to ensure the safety of heat-sensitive food products. The company offers a unique product in the form of a plastic sticker attached to food packaging. This sticker changes color in response to heat exposure, allowing consumers to easily assess whether the food is safe for consumption. By informing consumers about the safety and quality of their food, Fresh Strips addresses a critical need in the food industry, enhancing consumer confidence and reducing food waste.

Ormet Circuits, Inc. specializes in designing, manufacturing, and selling electrically conductive sintering pastes and inks tailored for the microelectronics and printed circuit board industries. Founded in 2001 and located in San Diego, California, the company provides a range of lead-free copper-based sintering pastes that facilitate the assembly of advanced electronic devices. Their products are utilized in applications such as semiconductor packaging, die attach, photovoltaic systems, and as replacements for lead-free solder. Ormet's offerings include conductive pastes that fill micro via structures for Z-axis interconnections, as well as materials for creating circuit traces and thermally conductive die attach. The company operates globally through a network of distribution and representative organizations and is a subsidiary of Merck KGaA.

Qlight Nanotech specializes in the development of semiconductor nanocrystals that possess distinct optical and electrical properties. These nanocrystals facilitate the conversion of UV and blue light wavelengths to a broader spectrum within the visible range, with the specific color output determined by the size of the nanoparticles. When energized by light, these nanocrystals produce illumination that is both highly accurate in color and wavelength, as well as exhibiting significant quantum efficiency. This technology enhances energy efficiency and reduces costs, making it particularly beneficial for applications in solid-state lighting systems, flat panel displays, and other optical technologies. By minimizing energy loss during light frequency conversion, Qlight Nanotech's innovations contribute to improved performance in liquid crystal display screens and LED lighting solutions.

Sigma-Aldrich is a prominent life science and high technology company that specializes in providing a wide range of organic chemical products, kits, and services. These offerings are integral to scientific research, biotechnology, pharmaceutical development, and disease diagnosis, playing a crucial role in advancing scientific breakthroughs. The company's products are also essential components in various manufacturing processes within the pharmaceutical and diagnostic sectors, as well as other high-tech industries. Operating in 40 countries, Sigma-Aldrich employs around 7,600 individuals dedicated to delivering high-quality solutions and excellent service to clients worldwide.

AZ Electronic Materials S.A. is a producer and supplier of specialty chemical materials for the electronics market, catering primarily to manufacturers of integrated circuits and flat panel displays. The company operates through various segments, including IC Materials, Optronics, and Printing and Other. Its advanced technology products are essential for a range of applications, including integrated circuits, devices, light-emitting diodes, and photolithographic printing. With a focus on innovation, AZ Electronic Materials provides critical materials that support the development and manufacturing processes within the electronics industry.

CellASIC is a biotechnology company that develops microfluidic platform for live cell analysis experiments by facilitating long-term perfusion cell culture. The company engineers platforms that utilize cutting edge microfluidics technology to provide superior live cell analysis with dynamic flow control. The company is founded on 2005 and is headquartered in Hayward, California.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Seven Seas Ltd. provides vitamins, minerals, and supplements worldwide. It offers liver oils, health oils, jointcare products, multivitamins, skin nutrition products, pregnancy products, immune support products, cold and flu relief products, and pulse/cardiom products. The company’s products are used in various applications, such as everyday health, digestive health, exercise and sport, immunity, cold and flu relief, tiredness reduction, energy, brain health, hectic living, heart health, joint health, women's health, pregnancy nutrition, new mums, skin health, hair and nail health, menopause, children's health, teen health, 50+ health, and men's health.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative drugs targeting oncology and rare diseases. Based in Exton, Pennsylvania, the company focuses on utilizing DNA- and RNA-based drug candidates to treat a variety of conditions, including cancer, autoimmune disorders, and infectious diseases. Its lead product, Tilsotolimod, is a TLR9 agonist designed to enhance immune responses against solid tumors and is currently in clinical trials for several types of cancer. Idera also develops a range of other TLR-based compounds, including agonists and antagonists, to modulate immune responses. The company has established various collaborations with major pharmaceutical firms to advance its research and commercialization efforts, enhancing its capabilities in the biopharmaceutical landscape. Founded in 1989, Idera Pharmaceuticals continues to drive innovation in therapeutic solutions for unmet medical needs.

Suzhou Taizhu Technology Development Co., Ltd. is manufactures and supplies effect pigments for printing, plastics, coating, and cosmetics industries.

LITEC-LLL is develops, produces, and markets custom phosphors. It offers LED phosphors for lamps, and blue and UV-LEDs, as well as phosphor mixtures. The company also produces ortho-silicate lighting materials, as well as provides lighting engineering services.

BioVascular is a clinical-stage biotechnology company focused on developing innovative products for platelet-mediated cardiovascular diseases. Its lead product, saratin, is a recombinant polypeptide produced in yeast, originally discovered and licensed from Merck KGaA. The company is currently conducting human clinical trials for saratin, targeting its application in hemodialysis access grafts and peripheral artery grafts to mitigate intimal hyperplasia, a condition that can compromise graft functionality. BioVascular aims to address significant unmet medical needs by creating both drugs and devices that manage intimal hyperplasia and related cardiovascular issues, contributing to improved treatment and prevention strategies for vascular diseases in medical clinics.

Merck Serono S.A. discovers, develops, manufactures, and commercializes prescription medicines focusing on various therapeutic areas that include oncology, immuno-oncology, immunology, multiple sclerosis, fertility, endocrinology, biosimilars, and neglected diseases. It develop treatments to help manage neurodegenerative diseases, such as multiple sclerosis; colorectal cancer; drugs to treat head and neck cancer; fertility drugs for every stage of the reproductive cycle.

Survac ApS focuses on the development of peptide based therapeutic cancer vaccines. It intends to offer the vaccine candidates for licensing and collaboration agreements.

ProVantage Healthcare is a leading health benefit management company providing pharmacy benefit management and health information technology products and services to their customers. Their goal is to be the leading third-party supplier of products and services designed to optimize the quality and minimize the cost of healthcare services. As of January 1999, they provided services to over 3,500 customers, including pharmacy benefit management services covering approximately 4.5 million individuals and vision benefit management services covering approximately 500,000 individuals. In addition, their licensed products, which are designed to improve the quality of healthcare, are being used by their clients in programs covering over 13 million people. They have experienced significant growth since fiscal 1995, increasing revenues from $81.2 million to $643.3 million in fiscal 1998, representing a compound annual growth rate of approximately 99%. Approximately 75% of their growth in the number of people who use their pharmacy benefit management services during this period has been generated internally rather than through acquisitions.

Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.